New Cancer Therapy Findings from Sichuan University Reported (Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery)
By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting from Chengdu, People's Republic of China, by NewsRx journalists, research stated, "Nanoparticle-based drug delivery systems promise the safety and efficacy of anticancer drugs. Herein, we presented a facile approach to fabricate novel nanoparticles generated by PEG-Chrysin conjugates for the delivery of anticancer drug doxorubicin."
The news correspondents obtained a quote from the research from Sichuan University, "Chrysin was immobilized on the terminal group of methoxy poly(ethylene glycol) (mPEG) to form mPEG-Chrysin conjugate. The conjugates were self-assembled into nanoparticles. Doxorubicin (DOX) was loaded in the nanoparticles. The self-assembly, drug release profiles, interactions between nanoparticle and drug, cellular uptake and in vitro anticancer activity of the DOX loaded nanoparticles were investigated. The results showed that the mean diameters of drug loaded nanoparticles were below 200 nm. Strong pi-pi stacking interaction was tested within the drug loaded nanoparticles. The drug release rate was closely related to the chain length of PEG, shorter PEG chain resulted faster release. The mPEG-Chrysin conjugate was non-toxic to both 3T3 fibroblasts and HepG2 cancer cells. The cellular uptake measurements demonstrated that the mPEG(1000)-Chrysin nanoparticles exhibited higher capability in endocytosis. The IC50 of drug loaded mPEG(1000)-Chrysin nanopartides was 4.4 mu g/mL, which was much lower than that of drug loaded mPEG(2000)-Chrysin nanoparticles (6.8 mu g/mL)."
According to the news reporters, the research concluded: "These nanoparticles provided a new strategy for fabricating antitumor drug delivery systems."
For more information on this research see: Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(3):454-460. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
Our news journalists report that additional information may be obtained by contacting H. Zheng, Sichuan University, Sch Chem Engn, Chengdu 610065, People's Republic of China. Additional authors for this research include S. Li, Y.J. Pu, Y.S. Lai, B. He and Z.W. Gu (see also Oncology).
Keywords for this news article include: Chengdu, People's Republic of China, Asia, Drug Delivery Systems, Emerging Technologies, Nanoparticle, Nanotechnology, Oncology, Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC